Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Public ClinicalTrials.gov record NCT02397694. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy, safety and tolerability of bictegravir (BIC) + emtricitabine/tenofovir alafenamide (F/TAF) fixed dose combination (FDC) versus dolutegravir (DTG) + F/TAF in HIV-1 Infected, antiretroviral treatment-naive adults. This study will also evaluate the pharmacokinetic (PK) profile of BIC, emtricitabine and TAF.
Study identification
- NCT ID
- NCT02397694
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 98 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 22, 2015
- Primary completion
- Nov 29, 2015
- Completion
- Feb 26, 2019
- Last update posted
- Apr 6, 2020
2015 – 2019
United States locations
- U.S. sites
- 21
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85012 | — |
| Not listed | Los Angeles | California | 90036 | — |
| Not listed | Los Angeles | California | 90069 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | Washington D.C. | District of Columbia | 20009 | — |
| Not listed | Washington D.C. | District of Columbia | 20036 | — |
| Not listed | Fort Lauderdale | Florida | 33316 | — |
| Not listed | Orlando | Florida | 32803 | — |
| Not listed | West Palm Beach | Florida | 33401 | — |
| Not listed | Atlanta | Georgia | 30312 | — |
| Not listed | Decatur | Georgia | 30033 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Berkley | Michigan | 48072 | — |
| Not listed | Newark | New Jersey | 07102 | — |
| Not listed | Austin | Texas | 78705 | — |
| Not listed | Dallas | Texas | 75208 | — |
| Not listed | Houston | Texas | 77004 | — |
| Not listed | Houston | Texas | 77098 | — |
| Not listed | Longview | Texas | 75605 | — |
| Not listed | Annandale | Virginia | 22003 | — |
| Not listed | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02397694, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2020 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02397694 live on ClinicalTrials.gov.